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Interferons (IFNs) were discovered as cytokines induced during and protecting from viral infection. They have
been documented to play essential roles in numerous physiological processes beyond antiviral and antimi-
crobial defense, including immunomodulation, cell cycle regulation, cell survival, and cell differentiation.
Recent data have also uncovered a potentially darker side to IFN, including roles in inflammatory diseases,
such as autoimmunity and diabetes. IFN can have effects in the absence of acute infection, highlighting a
physiologic role for constitutive IFN. Type I IFNs are constitutively produced at vanishingly low quantities
and yet exert profound effects, mediated in part through modulation of signaling intermediates required
for responses to diverse cytokines. We review evidence for a yin-yang of IFN function through its role in
modulating crosstalk between multiple cytokines by both feedforward and feedback regulation of common
signaling intermediates and postulate a homeostatic role for IFN through tonic signaling in the absence of
acute infection.Three types of interferon (IFN) have been identified in mammals.
The type I IFN family encodes 7 subtypes, including 13 IFN-a iso-
forms, IFN-ε, IFN-k, IFN-u, and IFN-b. There is also a single type
II IFN (IFN-g) and the type III IFNs comprised of IFN-l 1, 2, and 3
(also named IL-29, IL-28a, and IL-28b, respectively) (Levy et al.,
2011; Li et al., 2009; Pestka et al., 2004). Type I IFNs are secreted
in abundance in response to viral infection, acting early during
the immune response to potentiate antiviral responses and to
prime andmaintain adaptive immunity (Durbin et al., 2000; Huber
and Farrar, 2011; Mu¨ller et al., 1994). Interestingly, low amounts
of IFN-b accumulate in the tissue milieu in the absence of infec-
tion. Until recently, the purpose of this constitutive IFN-b has
been unclear, in part because the quantities of constitutive IFN
are close to the threshold of detection of even the most sensitive
assays (Hamilton et al., 1996; Vogel and Fertsch, 1984). It has
been proposed that small quantities of IFN-b prime cells for an
efficient subsequent response to other cytokines and are also
necessary for immune homeostasis, maintenance of bone
density, and antiviral and antitumor immunity. Constitutive IFN
may also play detrimental roles, particularly when improperly
regulated, by augmenting an autoimmune-prone condition or
by enhancing potentially debilitating inflammation that could
lead to cancer (de Visser et al., 2006). It is important to build
an understanding of the molecular events that underpin con-
stitutive IFN production and action and of how defects in this
process impact disease.
Constitutive Type I IFN Secretion
In the early 1980s, Velio Bocci proposed a biological role for
constitutive IFN signaling based on observations that uninfected
tissue preparations produced an antiviral activity akin to IFN. It
was proposed that IFNwas induced by ongoing low-grade expo-
sure of the mucosa to external pathogens, tissue remodeling, or166 Immunity 36, February 24, 2012 ª2012 Elsevier Inc.damage (Bocci, 1980). Although the constitutive production of
type I IFN has not been addressed under germ-free conditions
to assess a potential role for commensal microorganisms, type
I IFN mRNA and protein have subsequently been detected in
tissues of healthy mice maintained in specific-pathogen-free
environments (Gresser, 1990; Tovey et al., 1987; Viti et al.,
1985; Yaar et al., 1986). The generation of neutralizing type I
IFN antibodies and later animals lacking the type I IFN receptor
(Ifnar) or the Ifnb gene provided essential tools to further substan-
tiate the existence and importance of constitutive type I IFN. It is
now clear that constitutive IFN-b occurs in healthy animals and
is necessary for a diverse array of biological effects, including
maintenanceof the hematopoietic stemcell (HSC) niche, immune
cell function, and bone remodeling. Moreover, perturbations
of IFN expression or signalling contribute to the pathology of
autoimmune disease, antiviral immunity, and cancer.
Mechanism of Constitutive Type I IFN Production
Although type I IFNs are encoded by multiple genes, they are
coregulated in a complex fashion involving a positive feedfor-
ward regulatory loop (Marie´ et al., 1998; Sato et al., 1998). In
the absence of priming amounts of IFN-b, mouse embryo fibro-
blasts (MEFs) do not produce other type I IFNs, suggesting that
IFN-b is a master regulator and highlighting the importance of
IFN-b secretion in regulating all type I IFN activities and presum-
ably those mediated by type III IFN (Erlandsson et al., 1998;
Takaoka et al., 2000). IFN-b mRNA expression increases
dramatically in response to viral infection; in this context the
occupancy of the IFN-b promoter and enhancer has been exten-
sively characterized. The IFN-b promoter contains four positive
regulatory domains (PRDI–PRDIV), which are occupied by over-
lapping transcription factor complexes. Interferon regulatory
factor 3 (IRF3) and IRF7 bind PRDI and III; the AP-1 heterodimer
Figure 1. Transcription Factors for
Inducible and Constitutive IFN-b Promoter
Activity
The Ifnb promoter contains four positive regulatory
domains (PRDI–PRDIV). Top: Stimulation-depen-
dent induction of Ifnb expression requires coop-
erative recruitment of a number of transcription
factor complexes to its promoter: IRF-3 and/or
IRF-7, ATF-2 and c-Jun, p50 and RelA, and the
architectural protein HMGA1 (not pictured). The
binding of these factors to their specific regions
(IRF-3 and IRF-7 bind PRDI and PRDIII; ATF-2 and
c-Jun bind PRDIV; p50 and RelA bind PRDII) leads
to rapid and robust induction of Ifnb expression.
Bottom: In the absence of stimulation, the Ifnb
promoter is occupied by c-Jun at PRDIV and RelA
at PRDII, which promote basal Ifnb expression;
and IRF-2 at PRDI and p50 homodimers at PRDI,
PRDII, and PRDIII, which negatively regulate Ifnb production. Involvement of additional transcription factors, particularly partners for c-Jun and RelA in
unstimulated cells, remain to be identified.
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erodimer binds PRDII (Figure 1, top). In addition, roles for the
architectural protein HMGA1 and for a positioned nucleosome
have been defined (Ford and Thanos, 2010; Maniatis et al.,
1998). The binding of each of these components in the correct
orientation and location results in activation of the IFN-
b promoter in response to viral infection. For virus-induced
IFN-b expression, IRF3 and IRF7 appear to be essential (Hata
et al., 2001; Sato et al., 2000).
Less is known regarding the transcriptional regulation of
constitutive IFN-b. The most notable distinction from acutely
induced IFN expression is a switch from dependency on IRF3
and IRF7 to c-Jun and NF-kB components (Figure 1, bottom).
In contrast to pathogen-induced IFN-b production, deletion of
IRF3 does not prevent constitutive IFN-b expression (Hata
et al., 2001). In addition, deletion of IRF9 resulting in undetect-
able amounts of IRF7 has no impact on constitutive IFN-b
(Hata et al., 2001). However, AP-1 and NF-kB components
appear essential. AP-1 and NF-kB are dimeric transcription
factors, activated by a diverse array of cytokines and growth
factors. AP-1 is comprised of Jun, Fos, or ATF proteins; NF-kB
is comprised of a dimer of p50, p52, p65 (RelA), RelB, or c-Rel.
Although AP-1 and NF-kB play important but nonessential roles
in viral induction of IFN-b (Balachandran and Beg, 2011), both
are essential for constitutive IFN-b production. c-Jun occupies
PRDIV on the IFN-b promoter in uninfected cells, and its deletion
decreases constitutive IFN-b expression by half (Gough et al.,
2010). It is likely that the NF-kB subunit RelA also maintains
constitutive expression of IFN-b, as indicated by the fact that
RelA is bound to PRDII in unstimulated cells and loss of RelA
causes gene expression defects in unstimulated cells resem-
bling loss of IFN (Basagoudanavar et al., 2011; Wang et al.,
2010). However, constitutive IFN-b expression by Rela/
MEFs has not been directly measured.
Threshold expression of IFN-b in unstimulated cells is gov-
erned by IRF2 and p50 homodimers, both of which are constitu-
tively expressed and bind the IFN-b promoter as repressors
(Figure 1, bottom; Cheng et al., 2011; Senger et al., 2000; Thanos
and Maniatis, 1995; Harada et al., 1989). IRF2-deficient cells
have heightened expression of IFN-a and IFN-b and IFN target
genes and Irf2/ mice develop a psoriasis-like skin disease
that is ameliorated by removing IFN signaling, such as ablationof IFNAR1 (Arakura et al., 2007; Honda et al., 2003). The abun-
dance of constitutive IFN-b after loss of p50 has not been
measured; however, p50-deficient animals are developmentally
normal with no signs of the skin disease caused by IRF2 loss,
suggesting a lesser role for p50 as a repressor of constitutive
IFN-b (Sha et al., 1995). Together, these reports document that
the IFN-b promoter is occupied by both transcription activators
(c-Jun and RelA) and suppressors (IRF2 and p50 homodimers),
the balance of which maintain tight control of constitutive
IFN-b in the absence of overt stimulation.
Regulation of Cytokine Signal Transduction by
Constitutive IFN-b Secretion
Binding of type I IFNs to IFNAR (Pestka et al., 2004) activates
receptor-associated Janus kinases (JAKs) (Bach et al., 1997),
which phosphorylate the receptor and activate latent signal
transducers and activators of transcription (STATs) by receptor
recruitment and phosphorylation on a caboxy-terminal tyrosine
residue (Levy and Darnell, 2002; Stark et al., 1998). Activated
STATs form higher-order transcription factor complexes
(Schroder et al., 2004), which translocate to the nucleus and
bind to promoter elements to induce target gene expression
(Figure 2). These transcription factor complexes include STAT1
homodimers and a heterotrimer of STAT1, STAT2, and IRF9,
known as ISGF3 (Levy et al., 1988). STATs 3, 4, 5, and 6 can
also be phosphorylated in response to type I IFNs, forming
both homodimers and heterodimers (Platanias, 2005).
Somewhat paradoxically, loss of constitutive IFN-b or loss of
IFN responsiveness (e.g., as observed in Ifnar1/ animals)
attenuates cellular responses not only to type I IFNs but also to
unrelated cytokines, such as IFN-g and IL-6. Several hypotheses
have been advanced to explain this phenomenon. In one model,
IFN augments other cytokine responses by direct interaction of
heterologous receptors, allowing corecruitment of downstream
effector molecules. To date there have been two such hybrid
receptors proposed: the association of IFNAR1 with IFN-gR2
(Takaoka et al., 2000) and the association of IFNAR1 with the
common gp130 chain of the IL-6 receptor (Mitani et al., 2001).
It was proposed that constitutive IFN-b secretion leads to the
assembly of these multimeric receptors, and cytokine-depen-
dent receptor crosstalk augments tyrosine phosphorylation of
IFNAR1, providing a docking site for latent STAT1 or STAT3,Immunity 36, February 24, 2012 ª2012 Elsevier Inc. 167
Figure 2. Constitutive IFN-b Signaling Sets the Balance of Signaling Intermediaries
In a healthy organism, low amounts of IFN-b are constitutively secreted, which maintains appropriate expression of IFN-inducible signaling intermediaries,
including the transcription factors STAT1, STAT2, IRF5, IRF7, and IRF9 (center). Appropriate expression allows a balance between STAT1 or ISGF3 signaling and
signaling through other STAT proteins (e.g., STAT4). Diminished constitutive IFN-b secretion (left) results in decreased expression of ISGF3 subunit proteins,
altering the balance of signaling (e.g., between ISGF3 and STAT4) and culminating in susceptibility to infection and cancer, inefficient hematopoietic stem cell
(HSC) mobilization, and increased bone resorption. Excessive expression of IFN-b (right) drives overexpression of ISGF3 proteins, initiating an inflammatory
environment that can result in autoimmunity and exhaustion of the HSC niche.
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This model could account for cooperation between type I and
II IFN and IL-6; however, this model would also suggest far
greater overlap in the transcriptional response and biological
outcome to stimulation with these cytokines than has actually
been observed (Der et al., 1998; Weihua et al., 2000).
An alternative model posits regulation of signaling intermedi-
aries by priming amounts of IFN-b, rather than direct receptor
crosstalk. In this model, low-level IFN-b signaling is required to
maintain adequate expression of STAT1 and 2, and probably
a host of other signaling components, all of which are STAT
target genes. In the absence of constitutive IFN-b or its receptor,
basal STAT expression is diminished, compromising STAT-
dependent biological responses, such as those induced by
IFN-g and IL-6 (Figure 2). Cells with defects in IFN-b signaling
have decreased basal expression of STAT1 and STAT2
compared to wild-type cells (Fleetwood et al., 2009; Gough
et al., 2010). Furthermore, gene expression studies demon-
strated that basal expression of other signaling molecules is
affected by loss of constitutive IFN-b signaling, including168 Immunity 36, February 24, 2012 ª2012 Elsevier Inc.reduced IRF1, IRF7, and possibly STAT3 (Fleetwood et al.,
2009; Gough et al., 2010; Thomas et al., 2006). STAT6 is also
IFN responsive and therefore is probably diminished in the
absence of constitutive IFN-b (de Veer et al., 2001). Given the
many intermediary cytokine signaling molecules that are them-
selves induced by JAK-STAT activation, loss of basal signaling
probably leads to a paucity of intermediary proteins required
for an array of diverse responses. This model would explain
the attenuated signaling and biological activity of other cytokines
that engage the STAT pathways, such as reduced IFN-g, IL-6,
and CSF-1 signaling observed in Ifnar1/ cells (Gough et al.,
2010; Karaghiosoff et al., 2000; Park et al., 2000; Thomas
et al., 2006). This hypothesis of a direct priming role for constitu-
tive IFN would also account for the observation that treatment
of Ifnar1/ macrophages with subthreshold concentrations of
IFN-g increases both basal STAT1 expression and subse-
quent IFN-g-induced STAT1 phosphorylation (Hu et al., 2002).
Because reduced responsiveness is due to limited STAT1 abun-
dance, increasing STAT1 expression can rescue signaling, re-
gardless of the receptor complex involved. However, recovery
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NAR would not be predicted by a receptor cross-talk model.
An extension to the IFN priming hypothesis is that the ratio of
specific STAT proteins shapes the biological response to a stim-
ulus. In the case of Ifnar1/ or Ifnb1/ cells, STAT1 and STAT2
expression is diminished, providing a stoichiometric advantage
to other STAT proteins for receptor binding. An example of the
biological relevance of STAT protein ratios is the IL-6 to IFN-g
switch caused by reduced STAT3 expression. IL-6 signaling in
the absence of STAT3 exhibits a transcriptional and biological
profile similar to that of IFN-g by preferentially engaging STAT1
(Costa-Pereira et al., 2002). The inverse happens in response
to IFN, leading to enhanced antiviral signaling resulting from
the absence of the tonic effect of STAT1-STAT3 competition
(Wang et al., 2011). Because constitutive IFN-b is a critical regu-
lator of STAT protein expression, it is capable of sculpting subse-
quent responses to diverse stimuli of the JAK-STAT pathway by
shifting the ratio of available STATs. Taken together, these find-
ings suggest that the precise setpoint of STAT and other
signaling protein abundance, maintained by basal IFN signaling,
is a critical regulator of the quantity and quality of subsequent
responses.
Biological Significance of Constitutive IFN Secretion
Constitutive type I IFN is important for the maintenance and
mobilization of the hematopoietic stem cell niche (Essers et al.,
2009; Sato et al., 2009). Treatment ofmicewith poly(I:C), a strong
inducer of type I IFNs, or with IFN-a itself, causes HSC exit from
G0 and temporarily induces proliferation of dormant HSCs (Ess-
ers et al., 2009; Sato et al., 2009). Mice lacking IFNAR1 are
refractory to type I IFN and therefore their HSC compartment
remains quiescent in response to either poly(I:C) or IFN-a treat-
ment (Essers et al., 2009; Sato et al., 2009). These studies docu-
mented a role for induced IFN in the regulation of hematopoietic
expansion, but analysis of the bone marrow of unmanipulated
Ifnar1/ animals revealed a role for constitutive IFN in HSC
homeostasis. Ifnar/ mice display a reduction in the total
number of HSCs compared to wild-type animals (Essers et al.,
2009), suggesting that tonic IFN signaling maintains the HSC
compartment. Because bone marrow from Ifnar1/ mice is
capable of reconstituting the hematopoietic compartment of
lethally irradiated wild-type hosts (Diamond et al., 2011; Dunn
et al., 2005), some of the tonic effects of IFN probably act on
the bone marrow stroma in the HSC niche. Mice lacking
STAT1 have a defective response to poly(I:C) similar to Ifnar1/,
suggesting that IFN-a-induced HSC proliferation is STAT1
dependent (Essers et al., 2009).
IRF2, as a negative regulator of IFN-b expression, modulates
the concentration of constitutively secreted IFN-b (Arakura
et al., 2007; Honda et al., 2003; Senger et al., 2000). Increased
IFN-b secretion in Irf2/ mice leads to the exhaustion of the
HSC niche, similar to that observed after prolonged IFN treat-
ment. This depletion of HSCs can be averted by ablation of Ifnar1
(Sato et al., 2009). These data can be explained by positing that
constitutive type I IFN is normally at a concentration below the
threshold necessary to mobilize HSCs but at a level sufficient
to maintain the HSC niche. Therefore, either the absence of
constitutive IFN or prolonged elevated IFN depletes the HSC
niche, although as a result of opposing underlying mechanisms.Immune Cell Homeostasis and Activity
The importance of constitutive IFN-b in maintaining immune
homeostasis has been revealed by studies examining the aber-
rant phenotype of mice lacking type I IFN receptors. IFNAR-defi-
cient mice have decreased splenic NK cells and B220-positive B
lymphocytes and increased Gr1+CD11c+ myeloid cells (Hwang
et al., 1995; Swann et al., 2007). In the absence of constitutive
IFN-b signaling, murine hematopoietic cells exhibit enhanced
proliferative responses to low doses of CSF-1 and increased
expression of the activation markers CD11c and CD11b (Hamil-
ton et al., 1996; Honda et al., 2003; Hwang et al., 1995; Teige
et al., 2003).
Constitutive IFN-b augments myeloid cell function andmacro-
phage homeostasis, as shown by analysis of macrophages from
C3H-HeJ mice, which are incapable of inducing IFN in response
to LPS because of a defect in the Tlr4 gene (Poltorak et al., 1998).
Culturing C3H-HeJ macrophages with supernatants from
wild-type C3H-HeN macrophages that express constitutive
IFN-b enhanced their phagocytic potential. A similar effect was
obtained by adding low ‘‘priming’’ concentrations of IFN to
C3H-HeJ macrophages (Vogel and Fertsch, 1984). Conversely,
phagocytic potential was attenuated when C3H/HeN macro-
phages were incubated with IFN-a- and IFN-b-neutralizing
antibodies (Vogel and Fertsch, 1984), documenting the require-
ment for constitutive IFN in maintaining macrophage function.
The physiologic consequence of the importance of constitutive
IFN for macrophage function may be reflected by the influence
of the gut microbiota on hematopoietic homeostasis through
basal TLR signaling (Musso et al., 2011).
Given the role of constitutive IFN-b in regulating macrophage
activity, effects on other myeloid lineages could be expected.
For instance, osteoclasts are required for bone remodeling and
are therefore critical for maintaining bone homeostasis. Consti-
tutive IFN-b impairs bone marrow-derived macrophage differen-
tiation into osteoclasts, resulting in reduced bone resorption.
This is seen most clearly in vivo by comparing wild-type, Ifnb/,
and Ifnar1/ mice; the mutant strains exhibit decreased bone
density and increased numbers of osteoclasts (Takayanagi
et al., 2002). Therefore, constitutive IFN-b probably maintains
the entire myeloid lineage at correct homeostatic numbers,
which has implications for both the regulation of the innate
immune system and maintenance of the skeletal system.
Type I IFN has complex effects on T cells. It is a potent
suppressor of proliferation in most cell types, but it enhances
the survival and proliferation of CD8+ blasts (Marrack and Kap-
pler, 2004). Unexpectedly, Ifnar1- and Ifnb-deficient animals do
not have altered CD8+ T cell numbers; however, after peptide
or DNA-based immunization, these mice accumulate twice the
number of antigen-specific CD8+ T cells compared to wild-
type (Dikopoulos et al., 2005). One explanation for this apparent
contradiction is the relative ratios of STAT proteins expressed.
IFNAR-deficient cells express lower amounts of STAT1, enabling
JAK-STAT signaling to favor STAT4 over STAT1 (Figure 2).
STAT4 stimulates T cell proliferation and production of the Th1
cell subset of CD4+ cells and is a master regulator of IFN-g
secretion from NK cells. In contrast, STAT1 activation is typically
growth inhibitory and impedes IFN-g secretion from NK cells
(Miyagi et al., 2007; Nguyen et al., 2002). In addition, CD8+
T cells have a less robust induction of STAT1 expression thanImmunity 36, February 24, 2012 ª2012 Elsevier Inc. 169
Immunity
Reviewdo CD4+ T cells (Gil et al., 2006), which would compound the
STAT1 to STAT4 switch and lead to reduction in IL-10-producing
CD4+ T regulatory cells (Dikopoulos et al., 2005).
Constitutive type I IFN is involved in themaintenance of NK cell
biology at several levels. The primary cytokine necessary for NK
cell proliferation is IL-15, which is a type I IFN-regulated gene
(Fehniger et al., 2001; Kennedy et al., 2000; Lodolce et al.,
1998; Montoya et al., 2002). Although IL-2 can equivalently
support STAT1-deficient NK cell growth, IL-15 is able not only
to support growth but also to restore cytotoxicity to Stat1/
NK cells (Lee et al., 2000). Because of the inability of Ifnar1/
or Ifnar2/ mice to respond to constitutively secreted IFN-b, it
was unsurprising to find that the number of NK cells in these
animals was lower than in wild-type animals and that these
mice were highly susceptible to the outgrowth of NK-targeted
tumor cells (Swann et al., 2007). Again, these effects occur in
the absence of an overt pathogenic stimulation, suggesting
that the mutant animal phenotype is caused by loss of tonic
IFN signaling. In addition to a proliferative defect, NK cells
derived from Ifnar2/mice are defective in IL-2-mediated killing
of RMAS cells in vitro, although the cytotoxicity of naive IFNAR-
deficient NK cells to some targets is not affected (Lee et al.,
2000; Swann et al., 2007). In contrast, complete absence rather
than just reduced expression of STAT1 results in a profound
defect in NK cell cytotoxicity (Lee et al., 2000). Interestingly,
the dichotomy of STAT1 and STAT4 expression also influences
the activity of NK cells. Basal expression of STAT4 is higher
than that of STAT1 in NK cells (Mack et al., 2011), where it drives
IFN-g production (Mack et al., 2011; Miyagi et al., 2007). IFN
generated during infection increases STAT1 expression in NK
cells, which displaces STAT4 on IFNAR leading to suppression
of IFN-g production (Mack et al., 2011; Miyagi et al., 2007). NK
cells from Ifnar1/ animals have attenuated STAT1 expression
(Miyagi et al., 2007). Abundant STAT1 and STAT2 leads to stim-
ulation of NK cell-mediated cytotoxicity, whereas reduced
STAT1 but abundant STAT4 stimulates cytokine secretion at
the expense of cytotoxicity (Nguyen et al., 2002). Because the
ratios of STAT proteins are set by tonic IFN signaling, constitutive
IFN is critical for modulating subsequent cellular responses.
These observations highlight another important consequence
of constitutive IFN: to modulate relative expression of STAT
proteins. STAT1, STAT2, and STAT6 are all IFN-responsive
genes and as such constitutive IFN governs their abundance
(de Veer et al., 2001). We have recently confirmed that absence
of constitutive IFN signaling, either because of genetic ablation
of Ifnar1 or by treatment with blocking antibodies, markedly
reduced STAT1 and STAT2 expression in a range of primary
tissues, including dendritic cells, splenocytes, fibroblasts, heart,
large intestine, small intestine, liver, lung, and pancreas (Gough
et al., 2010). This observation suggests that the ratio between
STAT1 and other STATs is governed by constitutive IFN-b, es-
tablishing homeostatic regulation of multiple lineages. Taken
together, these observations demonstrate that basal levels of
STATs and other proteins is maintained through tonic IFN
signaling.
Antiviral and Antitumor Effects
Type I and type II IFNs bind to distinct receptors and therefore it
was assumed that loss of IFNAR would have no effect on IFN-g170 Immunity 36, February 24, 2012 ª2012 Elsevier Inc.signaling. Surprisingly, it was found that IFN-g-dependent anti-
viral responses are compromised in the absence of IFNAR1
(Gough et al., 2010; Mu¨ller et al., 1994; Takaoka et al., 2000).
The importance of constitutive IFN-b secretion in maintaining
IFN-g-dependent antiviral activities has been highlighted in
a number of experimental observations. Priming IFN-b-deficient
MEFs with low dose IFN-b restored IFN-g-mediated antiviral
responses and increased resistance to influenza virus by
promoting activation of DCs (Phipps-Yonas et al., 2008; Takaoka
et al., 2000). Because maintenance of STAT1 expression in
MEFs is dependent on constitutive IFN-b, absence of IFN
responsiveness (e.g., Ifnar1/ or Ifnb1/ mice) attenuated
IFN-g-mediated antiviral responses. Ectopic restoration of
STAT1 to physiologic expression in IFNAR-deficient cells
rescued IFN-g-mediated antiviral protection without altering
the response to type I IFN (Gough et al., 2010). Positive correla-
tion between the abundance of constitutive IFN-b and subse-
quent antiviral responses has also been observed in physiologic
situations. For example, cardiac myocytes have higher constitu-
tive IFN-b expression than do cardiac fibroblasts, and myocytes
show increased resistance to viral infection (Zurney et al., 2007).
Type I IFN is used as a treatment for viral infection (hepatitis B
and C) and cancer (including chronic myeloid leukemia and
melanoma) and its efficacy is affected by constitutive IFN. Mela-
noma is often refractory to IFN-a and IFN-b treatment relative to
normal tissue. This loss of IFN responsiveness is associated with
reduced STAT1 expression (Landolfo et al., 2000; Sun et al.,
1998; Wong et al., 1997) and restoration of STAT1 expression
to amounts seen in normal tissue via transduction or priming
with IFN-g regained responsiveness to type I IFN treatment
(Wong et al., 1997, 1998). Other studies have shown that low
amounts of IFN-b repress tumor growth by preventing produc-
tion of proangiogenic cytokines by tumor-infiltrating neutrophils
(Jablonska et al., 2010). Defects in type I IFN secretion and/or
signaling have also been seen in other human malignancies,
including the deletion of IFN genes in acute leukemia cells (Cola-
monici et al., 1992) and malignant T cells (Heyman et al., 1994);
downregulation of IFNAR in hairy cell leukemia (Billard et al.,
1986), gastric cancer (Chen et al., 2009), and lymphoblastoid
cells (Pfeffer and Donner, 1990); loss of JAK1 in lung carcinoma
(Kaplan et al., 1998); downregulation of IFN signaling compo-
nents in melanoma (Wong et al., 1997) and chronic myeloid
leukemia (Landolfo et al., 2000); and overexpression of negative
regulatory SOCS proteins in cancer (Lesinski et al., 2010; Li et al.,
2004). The number and variety of malignancies with mutations
that prevent production of or alter responsiveness to IFN
suggests that aberrations in IFN sensitivity and production
provide a survival advantage for tumor cells and thus a potential
target for therapeutic intervention.
Autoimmunity
The development and progression of autoimmune diseases is
multifactorial; however, increased secretion of type I IFN or an
IFN-stimulated gene signature is typical in patientswith a number
of diseases, such as systemic lupus erythematosus (SLE), Sjo¨g-
ren’s syndrome, or type I diabetes mellitus (DM), correlating with
increased disease severity (Crow, 2010; Kirou et al., 2005; Lu
et al., 2007). A subset of patients receiving IFN treatment for
hepatitis C develop DM, arthritis, or multiple sclerosis (MS)
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fact that IFN-b is commonly used to treat MS (Buttmann and
Rieckmann, 2007; Tak, 2004). Similarly, there is a subset of MS
patients that do not respond to IFN-b treatment. Nonresponders
present with high circulating amounts of IFN-b, suggesting that
a precise setpoint of IFN-b concentration must be maintained;
both higher or lower amounts result in pathologic consequences
(Comabella et al., 2009).
Elevated IFN-a expression in SLE patients may be responsible
for the generation of autoimmune antibodies by inducing mono-
cyte differentiation and potentiating activation of CD4+ T cells in
response to self antigens (Blanco et al., 2001). The pathologic
consequence of elevated IFN in SLE is revealed by disease
amelioration in mice by IFNAR deficiency. Moreover, IFN-
neutralizing antibodies have shown promise in clinical trials in
SLE (Nacionales et al., 2007; Yao et al., 2009).
As noted above, IRF-2 deficiency leads to psoriasis because
of elevated IFN (Arakura et al., 2007). The AP-1 and NF-kB
subunits c-Jun and RelA that drive constitutive IFN-b expression
are elevated in psoriatic plaques (Lizzul et al., 2005; Mehic et al.,
2005; van der Fits et al., 2003). No discrete pathogens have been
implicated in disease causation, suggesting that altered tonic
type I IFN signaling contributes to the pathogenesis of psoriasis.
These data support a unified concept of IFN-mediated
homeostasis. Appropriate amounts of basal IFN maintain the
abundance of a wide variety of signaling molecules important
for both immunity and tissue homeostasis. Neither reduced nor
enhanced levels of IFN can be tolerated without adverse conse-
quences of either impaired hematopoietic homeostasis and
reduced immune responses on the one hand or increased
inflammation and autoimmunity on the other. It will be of great
interest to understand the contribution of the microbiome to
both the appropriate and the inappropriate regulation of tonic
IFN (Musso et al., 2011).
Concluding Remarks
IFN-b and other type I IFNs are constitutively secreted at low
amounts by many tissues of the body as a means of maintaining
homeostasis and priming cells to maintain a rapid and robust
innate and adaptive immune response to subsequent challenge.
It will be important to determine whether there are other similar
biological processes whereby constitutive low-level autocrine
or paracrine cytokine signaling maintains homeostatic balance.
The range of influences of constitutive IFN-b is due, in large
part, to its role in maintaining the expression of STAT proteins
and other signaling intermediates, although the full range of
signaling proteins whose basal abundance is determined by
tonic IFN signaling remains to be documented. The loss of
priming concentrations of IFN-b leads to compromised expres-
sion of STAT and other regulatory proteins, resulting in impaired
cross-talk between cytokine signaling networks and a host of
additional phenotypes, such as aberrant immune cell function,
bone remodeling, and deregulation of HSC homeostasis. Docu-
menting the extent of innate and adaptive immune pathways
influenced by IFN priming will be an important area of further
investigation. Modulation of the abundance of signaling interme-
diates by constitutive IFN regulates both the quantity and the
quality of subsequent responses, resulting from competitive
interactions among related proteins. This mechanism potentiallyexplains many situations of cross-talk between diverse cytokine
families that signal through overlapping components subject to
feedback and feedforward regulatory networks. Increased
research into the regulation and function of tonic IFN signaling
and identification of the relevant IFN-stimulated genes that
contribute to homeostasis could have major implications for
our understanding of how a healthy immune system is main-
tained. Of importance will be development of a more complete
picture of the sources of tonic IFN, in particular determining
the contribution of environmental signals, such as influences
from microbial flora.
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